0001209191-17-031259.txt : 20170510 0001209191-17-031259.hdr.sgml : 20170510 20170510162510 ACCESSION NUMBER: 0001209191-17-031259 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20170504 FILED AS OF DATE: 20170510 DATE AS OF CHANGE: 20170510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Regulus Therapeutics Inc. CENTRAL INDEX KEY: 0001505512 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264738379 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10614 SCIENCE CENTER DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-202-6300 MAIL ADDRESS: STREET 1: 10614 SCIENCE CENTER DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chevallard Daniel R. CENTRAL INDEX KEY: 0001706176 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35670 FILM NUMBER: 17830645 MAIL ADDRESS: STREET 1: C/O REGULUS THERAPEUTICS INC. STREET 2: 10614 SCIENCE CENTER DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2017-05-04 0 0001505512 Regulus Therapeutics Inc. RGLS 0001706176 Chevallard Daniel R. C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DR. SAN DIEGO CA 92121 0 1 0 0 Chief Financial Officer Common Stock 4470 D Stock Option (Right to Buy) 4.81 2022-12-02 Common Stock 58000 D Stock Option (Right to Buy) 6.13 2023-12-11 Common Stock 35000 D Stock Option (Right to Buy) 17.76 2024-12-01 Common Stock 35000 D Stock Option (Right to Buy) 5.77 2026-01-31 Common Stock 40000 D Stock Option (Right to Buy) 3.52 2026-10-04 Common Stock 44537 D Stock Option (Right to Buy) 1.20 2027-02-14 Common Stock 25000 D Stock Option (Right to Buy) 5.77 2026-01-31 Common Stock 20000 D The option is fully vested and exercisable. 25% of the shares vested on December 11, 2014 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on December 11, 2017. 25% of the shares vested on December 2, 2015 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on December 2, 2018. 25% of the shares vested on February 1, 2017 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on February 1, 2020. 25% of the shares vest on October 5, 2017 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on October 5, 2020. 25% of the shares vest on February 15, 2018 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on February 15, 2021. 50% of the shares vested on January 30, 2017 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on January 30, 2019. Christopher Aker, Attorney in Fact 2017-05-10 EX-24.3_722594 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Christopher Aker of Regulus Therapeutics Inc. (the "Company"), signing individually, the undersigned's true and lawful attorney-in fact and agent to: (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by the Company. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of May, 2017. /s/ Daniel R. Chevallard _________________________ Daniel R. Chevallard